RESEARCH ARTICLE





Elective neck dissection improves the survival of patients with T2N0M0 oral squamous cell carcinoma: a study of the SEER database

Alimujiang Wushou^{1,2}, Feiluore Yibulayin³, Lu Sheng^{1,2}, Yuan Luo^{1,2} and Zhi-cheng Yang^{1,2*}

Abstract

Background: Treatment of clinical N0 neck tumours is controversial in early-stage oral squamous cell carcinoma (OSCC), possibly because T1N0M0 and T2N0M0 merge together at early stages. The purposes of this study were to compare survival outcomes only for T2N0M0 cases based upon treatment elective neck dissection versus neck observation.

Methods: T2N0M0 OSCC cases were identified in the Surveillance, Epidemiology, and End Results database of the United States National Cancer Institute between 2004 and 2015. Survival curves for different variable values were generated using Kaplan-Meier estimates and compared using the log-rank test. Variables that achieved significance at P < 0.05 were entered into multivariable analyses via the Cox proportional hazards multivariate regression.

Results: A total of 2857 patients were selected, and 2313 cases were available for disease specific survival (DSS). The 5-year and 10-year overall survival (OS) were 66.7 and 46% for patients receiving elective neck dissection (END), respectively, and 56.4 and 37.2% for patients with neck observation (P < 0.0001). The 5-year and 10-year DSS were 73.6 and 64% for the END group, respectively, versus 64.5 and 54.5% for the neck observation group (P < 0.0001). More importantly, performing END was independently associated with favourable DSS and OS for patients with T2N0M0 OSCC [hazard ratio (HR) = 0.769, P = 0.0069 for DSS; HR = 0.829, P = 0.0031 for OS, neck observation group as reference] according to multivariate survival analysis.

Conclusion: END is recommended for T2N0M0 OSCC cases and it is associated with improved DSS and OS. **Keywords:** Oral squamous cell carcinoma, T2N0M0, Elective neck dissection, Surgical treatment, SEER database

Background

Head and neck squamous cell carcinoma is increasingly prevalent worldwide and is the 16th leading cause of cancer death. Oral squamous cell carcinoma (OSCC) is the most common cancer of the oral cavity,

*Correspondence: Zhicheng_yang1998@fudan.edu.cn

² Shanghai Key Laboratory of Craniomaxillofacial Development

and Diseases, Fudan University, 356 Beijing East Road, Shanghai 200001, PR China

representing more than 95% of all cases and making up almost half of newly diagnosed head and neck squamous cell carcinoma [1, 2]. Overall survival (OS) rates of OSCC varied from 10 to 82% depending on various prognostic factors, including age, race, sex, primary site, drinking, smoking, human papillomavirus status, American Joint Committee on Cancer (AJCC) stage, pathological differentiation and treatment modalities [3]. Among these prognostic factors distant metastasis is one of the strongest indicators. Another important



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Full list of author information is available at the end of the article

prognostic factor in survival is the presence of lymph node metastasis. It has been reported that cervical lymph node metastasis and extranodal extension are prerequisites for distant metastasis development [4].

The existence of cervical lymph node metastasis demonstrates the most important clinico-pathological prognostic factor. The presence of even one positive cervical lymph node is associated with a 50% reduction in the OS [5]. Thus, appropriate treatment of the cervical lymph node is as important as treating the primary site to achieve good oncologic results. The optimal treatment protocol for patients with early stage (T1-2N0M0) tumours has been debated in the past several decades; no consensus has been reached because of similar prognosis between elective neck dissection (END) and neck observation. Head and neck surgical oncologists prefer preventive END to avoid regional recurrence; supraomohyoid neck dissection is well established [6]. However, others believe END is an aggressive regime, especially for young female patients with T1N0M0 tumours, mostly because of the neck contour changes and some surgical complications. Therefore, a wait-and-watch policy is recommended, which favours regular consultation without simultaneous neck dissection [7].

The AJCC T stage is an independent prognostic indicator, and T2-stage OSCC has demonstrated worse prognosis than T1 [8]. However, most previous studies have merged T1 and T2 in early stages of evaluating prognosis [9]. When clinically dealing with T1- and T2-stage OSCC, surgeons have encountered challenging treatment strategies. Surgically treated T1-stage OSCC typically does not require defect repair or postoperative defects can be closed with adjacent flaps. However, the postoperative defect of T2-stage tumours often requires free flap repair and simultaneous END- facilitated oral defect reconstruction, which would improve the patient quality of life [10]. Therefore, when assessing prognosis, T1N0M0 and T2N0M0 stage tumours should be separately evaluated instead of together [11]. In view of organ preservation or surgical reconstruction, we believe that surgical treatment is better than radiotherapy, chemotherapy or their combination for T2N0M0 OSCC patients. Furthermore, simultaneously performing END can prevent regional recurrence and is helpful for performing free flap reconstruction. Lastly, postoperative defect repair and functional restoration will eventually improve overall survival. Here, in order verify our above postulated conditions, we present a retrospective investigation comparing survival outcomes only for T2N0M0 cases based upon treatment END versus neck observation.

Methods

Study cohort

The study population was extracted from the Surveillance, Epidemiology, and End Results (SEER) database of the United States National Cancer Institute using its software (https://seer.cancer.gov, SEER*Stat 8.3.6). Patients were identified via the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) as previously described [12]. Briefly, the OSCC cases were selected through the ICD-O-3 morphologic and topographic codes: 8050–8076, 8078, 8083, 8084, 8094, C01.9, C02.0, C02.1, C02.2, C02.8, C02.9, C03.0, C03.1, C03.9, C04.0, C04.9, C05.0, C06.0, C06.1 and C06.2.

We selected only pathologically confirmed T2N0M0 (AJCC stage II) OSCC primary cases. Patients receiving neck dissection were identified through the SEER fields for regional lymph node surgery. The variables in the analysis included tumour origination, marital status at diagnosis, age at diagnosis, sex, race, pathological differentiation, whether neck dissection was performed, treatment modalities, vital status and follow-up period. Our study used the established data and did not involve interactions with human subjects. Therefore, institutional review board approval was not required.

Statistical analysis

Differences in numerical variables were evaluated with Student's test or the non-parametric Wilcoxon test. Categorical variables were compared by the chi square test or Fisher exact test. Survival analysis were performed using the Kaplan-Meier estimates. Independent prognostic factors were identified via the Cox proportional hazards multivariate regression. Data analyzation were carried out applying Statistical Package for Social Sciences, Version 23.0, for Windows (SPSS, Chicago, IL) and statistical packages R (The R foundation; http://www.r-project. org; version 3.4.3), Empower R (http://www.empowersta ts.com, Boston, MA).

Results

Clinicopathologic characteristics

A total of 2857 patients were selected. The cohort consisted of 1691 males and 1166 females with a mean age of 64 years. Caucasian accounted for 84.6% (2418/2857) and black American 6% (172/2857) of the study population. The overall mean follow-up period was 54.2 months (range, 0–155 months). In more than half of the cases (1611/2857, 56.4%), the orientation was tongue. END was performed for 62.5% (1787/2857) patients. The overall clinicopathologic characteristics are summarized in Table 1.

For disease specific survival (DSS) analysis, 2313 cases were available, including 939 females and 1374 males.

ck observation P-value ve Dead P-value 3 75 0.396 9 1779 0.396 1 179 0.396 1 179 0.396 1 179 0.396 1 198 0.0000 2220 2200 0.0000 1 198 0.0000 2 0.0000 33 1 199 0.0000 1 169 0.0000 1 169 0.0000 1 169 0.0000 3370 0.6677 2337 0.6657 37 0.5053 37 0.5053 37 0.372 37 0.372 5 324 0.372 5 205 0.372 5 323 0.478 5 323 0.478 5 323 0.478		Overal	Overall survival					Diseas	Disease specific survival	survival			
Aire Aire Deal Patien crigination Flor of mouth 63 75 0.396 dum and Other Mouth 179 179 179 0.306 fungue Single 228 275 0.306 Married Jongue 20-29 20 0.000 Married 20-29 111 198 0.000 Astried 20-29 2 0.000 0.000 Single 20-29 111 198 0.000 Astried 20-29 111 198 0.000 Single 20-29 112 129 0.000 Aquety 20-29 110 137 72 Single 20-29 137 72 0.000 Age 60-69 133 137 72 Age 20-79 137 22 0.000 Male Age 246 323 0.667 Male 644 246 246<		Neck o	bservatio	_	Neck d	Neck dissection		Neck o	Neck observation	-	Neck d	Neck dissection	
corigination Floor of mouth 63 75 0.396 Gum and Other Mouth 179 179 179 0.396 Istatus at diagnosis Single 76 83 0.000 Married 330 220 0.000 Married 330 220 0.000 Married 330 220 0.000 Other status 111 198 0.000 Married 30-39 18 3 0.000 20-29 137 72 2 0.000 20-79 18 3 3 3 3 60-69 133 72 2 0.000 70-79 133 72 2 0.000 60-69 133 72 2 0.000 70-79 133 72 2 0.000 80 60-69 133 17 0.667 80 60-69 133 169 0.667 80 <th></th> <th>Alive</th> <th>Dead</th> <th><i>P</i>-value</th> <th>Alive</th> <th>Dead</th> <th>P-value</th> <th>Alive</th> <th>Dead</th> <th><i>P</i>-value</th> <th>Alive</th> <th>Dead</th> <th><i>P</i>-value</th>		Alive	Dead	<i>P</i> -value	Alive	Dead	P-value	Alive	Dead	<i>P</i> -value	Alive	Dead	<i>P</i> -value
Gum and Other Mouth 179 179 179 Tongue 298 275 200 Tongue 298 275 200 Married 330 220 200 Married 330 220 0000 Other status 111 198 200 Other status 111 198 3 eriod 20-29 2 2 0000 30-399 18 3 2000 20 A0-49 5 20 2000 20 20 A0-69 137 72 26 28 27 S0-59 137 72 20 2000 Age 564 24 24 37 265 Age 564 24 24 37 266 Male 246 27 28 266 Male 246 27 29 266 Male 246 37 263 263	Floor of mouth	63	75	0.396	176	130	0.000	62	29	0.678	172	77	0.000
Iongue Tongue 298 275 Al status at diagnosis Single 76 83 0000 Married 330 220 83 0000 Married 330 220 83 0000 Other status 111 198 3 0000 Other status 111 198 3 0000 30-39 18 20-29 2 0000 30-39 18 20-29 2 2 0000 30-39 137 72 2 20 0000 60-69 137 72 2 2 0000 80+ 20 137 72 2 2 0000 80+ 137 72 2 2 2 2 0000 80+ 137 137 13 13 2 2 2 80 136 2 2 2 2 2 2 2 <	Gum and Other Mouth	179	179		249	195		177	96		244	111	
I status at diagnosis Single 76 83 000 Married 330 220 Married 330 220 Other status 111 198 Other status 111 198 Other status 111 198 Acried $20-29$ 22 0000 $30-39$ 117 128 30 $40-49$ 54 28 30 $60-69$ 139 119 32 $60-69$ 139 110 36 $60-69$ 139 119 32 $60-69$ 139 110 136 $60-69$ 139 110 136 $70-79$ 80 110 136 $60-69$ 139 129 2000 $80-7$ 100 129 200 $80-64$ 249 237 0667 $80-64$ 249 237 0667 $80-64$ 249 237 0667 $80-64$ 249 237 0667 $80-64$ 249 237 0667 $80-64$ 1000	Tongue	298	275		696	340		291	168		689	195	
Married 330 220 eriod 20-29 22 000 Other status 111 198 3 Other status 30-399 18 3 000 30-399 137 2 0000 3 30-399 137 2 2 0000 30-599 137 2 2 0000 30-60 139 137 2 2 0000 30-70 1010 137 2 2 0000 60 60 60 10 10 36 28 4diagnosis Age ≤ 64 246 370 0667 80 110 136 370 0667 Remale 72 246 237 0667 Mile 246 27 293 0.0006 80 177 133 0.0006 0.037 Indeck 246 27 26 27 0.0006		76	83	0.000	196	113	0.000	76	43	0.000	191	72	0.441
ceriod 111 198 ceriod 20–29 11 198 $30-39$ $30-39$ 18 3 $40-49$ 54 28 3 $40-49$ 54 28 3 $50-59$ 137 72 2000 $50-69$ 139 119 126 $60-69$ 139 119 126 $70-79$ $80+$ 80 169 1000 $70-79$ $80+$ 100 136 1000 $60-69$ 110 136 1000 110 $70-79$ $80+$ 100 136 0000 $80+$ $80 100$ 100 100 $40+$ 224 237 0000 1000 1000 216 207 0000 1000 1000 216 217 0100 1000 1000 100 100	Married	330	220		646	336		323	136		638	216	
eriod $20-29$ 2 2 000 $30-39$ $30-39$ 18 3 $40-49$ 54 28 28 $50-59$ 137 72 $60-69$ 139 119 $60-69$ 139 119 $70-79$ 80 169 $70-79$ 80 169 $80+$ $70-79$ 80 $80+$ $80 110$ $70-79$ $80 100$ $80+$ $80 100$ $80+$ $80 100$ $80+$ $80 100$ $80+$ $80 100$ $80+$ $80 100$ $80+$ $80 100$ $80+$ $80 1000$ $80+$ $80 1000$ $80+$ $80 1000$ $80+$ $80 1000$ $1000000000000000000000000000000000000$	Other status	111	198		217	192		108	66		214	87	
30-39 18 3 40-49 54 28 50-59 137 72 60-69 139 119 70-79 110 136 80+ 80+ 169 70-79 110 136 80+ 294 159 0.000 Age > 64 246 370 0.667 Age > 64 246 370 0.667 Nale Nale 246 370 0.667 Nale 246 370 0.667 Nale 246 370 0.667 Nale 246 37 0.667 Nale 246 37 0.667 Nale 246 37 0.667 No 0thers 25 29 Grade II 236 263 0.37 Kes 195 205 237 No Yes 195 205 Ment Surgery +RT 133 0.478 Surgery +RT 133 147	20–29	2	2	0.000	17	4	0.000	2	2	0.000	17	ŝ	0.000
40-49 54 28 $50-59$ 137 22 $50-69$ 139 119 $60-69$ 110 136 $70-79$ $80+$ 80 169 $70-79$ $Age > 64$ 294 159 0000 $Age > 64$ 249 237 0667 Age > 64 249 237 0667 Nale 249 237 0667 Nhite 249 237 0667 Age > 64 249 237 0667 Nhite 249 237 05653 Black 249 237 05653 Others 246 377 05653 Iogical grade 177 133 0.006 Grade II 236 263 293 0.006 Grade II 177 133 0.372 786 Kitherapy No 766 786 776 786 Kitherapy No 766 324 <	30–39	18	c		65	15		18	2		65	15	
50-59 137 72 60-69 139 119 $70-79$ 110 136 $70-79$ 110 136 $80+$ 80 169 169 $80+$ $29+$ 159 0.000 $Age > 64$ 294 159 0.000 Age > 64 246 370 0.667 Male 249 237 0.667 White Hendle 249 237 0.667 Male 291 292 0.000 0.006 Others Black 25 29 0.653 Black 25 29 0.653 0.653 Others 25 29 206 0.653 Iogical grade Grade II 177 133 0.006 Grade II 177 133 0.006 0.789 Ves 73 93 205 0.789 Ves 73 93 0.478 0.478 No 747 345 323 0.478 Nonge	40-49	54	28		179	58		53	23		177	44	
60-69 139 119 $70-79$ 110 136 $70-79$ 80+ 136 $80+$ 80 169 $80+$ 80 169 $80+$ 294 159 0.000 Age > 64 246 370 Age > 64 246 370 Male 249 237 0.667 White 249 237 0.667 White 249 237 0.667 Others 249 237 0.667 Nule 246 37 0.667 Others 249 237 0.667 Idojcal grade Grade II 236 237 Others 25 29 0.006 Grade II 236 263 37 Otherspy No 345 324 Otherspy No 345 205 Otherspy No 345 205 Otherspy No 73 93 Otherspy No 73 93 Otherspy 765 58 0.478 Ment Surgery HRT 133 0.478	50-59	137	72		325	137		137	49		320	92	
70-79 110 136 $80+$ 80 159 169 $80+$ Age ≤ 64 294 159 0.000 Age ≥ 64 246 370 2667 246 370 Age ≥ 64 246 370 2667 249 237 0.667 Age ≥ 64 246 246 370 2667 246 272 291 292 Nhite White 246 266 37 0.5657 291 292 Nhite Cathell 274 237 205 293 205 Iogical grade Grade II 236 263 263 263 263 Ioderapy No 73 236 263 205 205 Iotherapy No 746 77 232 205 205 Iotherapy No 747 233 0.478 278 Ment Surgery HRT 133 147 278 Surgery HRT 133 147 278 2478	60-69	139	119		296	194		138	64		292	104	
$80+$ 80 169 t diagnosis $Age \leq 64$ 294 159 0.000 $Age > 64$ 246 370 0.667 $Age > 64$ 246 370 0.667 $Male$ $Vhite$ 246 237 0.667 $White$ $Emale$ 249 237 0.667 $White$ $Cade$ 246 237 0.667 $White$ $Cade$ 246 237 0.563 $Black$ 25 29 0.006 $Grade II$ 236 263 0.372 $Grade II 236 263 0.006 Grade III + IV 73 93 0.006 Grade III + IV 73 93 0.372 Ves No Ves 0.345 207 Ment Surgery + RT 133 147 0.372 Ment Surgery + RT 133 147 0.372 $	70-79	110	136		182	163		105	77		177	79	
tdiagnosis Age ≤ 64 294 159 0.000 Age > 64 246 370 0.667 Age > 64 246 370 0.667 Alle 249 237 0.667 Male 249 237 0.667 White Emale 249 237 0.667 White 246 292 292 292 White 246 25 29 0.006 Black 25 29 0.006 37 Others 26 37 0.006 37 Iogical grade Grade II 236 263 263 Grade II 236 263 203 203 Otherapy No 345 324 0.372 Wite Ves 195 205 205 Ment Surgery +RT 133 147 20789	80+	80	169		57	94		77	76		57	46	
Age>64 246 370 er Female 249 37 0.667 Male 291 292 37 0.667 White Male 291 292 37 0.667 White Male 291 292 292 292 White Male 25 29 293 0.653 Black 25 29 37 0.667 Optical grade Grade II 177 133 0.006 Grade II 236 263 263 263 Interapy No 345 324 0.372 Interapy No 345 205 205 Interapy No 73 93 0.478 Ment Surgery +RT 133 147 0.789	Age ≤ 64	294	159	0.000	763	306	0.000	292	102	0.000	755	201	0.000
er Female 249 237 0.667 Male Male 291 292 0.667 White White 291 292 0.653 White Mote 264 462 0.653 Black 25 29 292 0.653 Others 25 29 263 0.37 Others $6rade 1$ 177 133 0.006 Grade II 236 263 263 263 Kherapy No 733 93 0.372 Kherapy No 733 93 0.372 Kherapy No 733 93 0.372 Kherapy No 736 205 0.372 Kherapy No 736 276 0.372 Kerapy No 736 276 0.372 Kerapy No 786 276 0.372 <	Age > 64	246	370		358	359		238	191		350	182	
Male 291 292 White 464 462 0.653 White 464 462 0.653 Black 25 29 0.653 Dothers 46 37 0.005 Others 67ade1 177 133 0.006 Grade11 177 133 0.006 Grade11 236 263 263 Otherapy No 73 93 0.372 Otherapy No 345 324 0.372 Otherapy No 73 93 0.478 Ment Surgery 345 323 0.478 Surgery +RT 133 147 0.372	Female	249	237	0.667	427	251	0.884	242	137	0.265	419	139	0.899
White 464 462 0653 Black 25 29 Dothers 46 37 Others 46 37 Others 63 0.006 Grade I 177 133 0.006 Grade II 236 263 93 Kiterapy No 345 324 0.372 Kiterapy No 345 205 0.789 Kes 195 205 0.789 0.789 Ment Surgery 345 323 0.478 Surgery +RT 133 147 0.789	Male	291	292		694	414		288	156		686	224	
Black 25 29 Others 46 37 Others 46 37 Grade I 177 133 0.006 Grade II 236 263 Grade III+IV 73 93 No 345 243 0.372 Yes 195 205 No 478 471 0.789 Yes 195 205 No 478 471 0.789 Yes 62 58 0.478 Surgery 345 323 0.478 Surgery +RT 133 147	White	464	462	0.653	920	570	0.100	454	251	0.786	908	322	0.623
Others 46 37 Grade I 177 133 0.006 Grade II 177 133 0.006 Grade II 236 263 263 Grade III+IV 73 93 93 No 345 324 0.372 Yes 195 205 93 No 478 471 0.789 Yes 62 58 93 Surgery 345 323 0.478 Surgery +RT 133 147	Black	25	29		76	42		25	17		74	26	
Grade1 177 133 0.006 Grade11 236 263 Grade11+IV 236 263 No 345 324 0.372 Yes 195 205 No 478 471 0.789 Yes 62 58 Surgery 345 323 0.478 Surgery +RT 133 147	Others	46	37		119	51		46	24		117	34	
Grade II 236 263 Grade III + IV 73 93 Grade III + IV 73 93 No 345 324 0.372 Yes 195 205 93 No 478 471 0.789 Yes 62 58 93 Surgery 345 323 0.478 Surgery + RT 133 147	Grade I	177	133	0.006	242	122	0.013	175	55	0.000	237	59	0.000
Grade III + IV 73 93 No 345 324 0.372 Yes 195 205 No 478 471 0.789 Yes 62 58 Surgery + RT 133 147	Grade II	236	263		683	398		232	154		674	229	
No 345 324 0.372 Yes 195 205 0.372 No 478 471 0.789 Yes 62 58 58 Surgery 345 323 0.478 Surgery +RT 133 147	Grade III + IV	73	93		161	129		71	66		160	87	
Yes 195 205 No 478 471 0.789 Yes 62 58 Surgery 345 323 0.478 Surgery +RT 133 147	No	345	324	0.372	694	378	0.035	339	159	0.006	685	191	0.000
No 478 471 0.789 Yes 62 58 58 Surgery 345 323 0.478 Surgery +RT 133 147	Yes	195	205		427	287		191	134		420	192	
Yes 62 58 Surgery 345 323 0.478 Surgery +RT 133 147	No	478	471	0.789	1034	599	0.076	469	250	0.022	1020	331	0.001
Surgery +RT 345 323 0.478 Surgery +RT 133 147	Yes	62	58		84	66		61	43		85	52	
133 147	Surgery	345	323	0.478	694	378	0.075	339	158	0.022	685	191	0.000
	Surgery +RT	133	147		340	221		130	91		335	140	
Surgery + RT + chemotherapy 62 57 87	Surgery + RT + chemotherapy	62	57		87	66		61	43		85	52	

 Table 1
 Clinico-pathological characteristic of study population

The mean follow-up period for DSS was nearly the same as OS. END was performed in 1488 cases in this cohort. Summary statistics of DSS status are presented in Table 1. When stratified by histologic grade, 528 cases were of grade I, 1289 cases of grade II, and the remaining 384 cases were of grades III and IV. Histologic grade information was missing for 111 cases. According to the distribution of sample sites, we divided the study population into three groups: (A) floor of mouth, (B) tongue and (C) other sites combined, including upper gum, lower gum, hard palate, cheek mucosa, vestibule of mouth and retromolar area.

Survival analysis


Kaplan-Meier analysis was applied for time-to-event analysis. Regardless of all other factors, the 5-year and 10-year OS were 66.7 and 46%, respectively, for patients receiving END and 56.4 and 37.2% for patients with neck observation (P < 0.0001, Fig. 1). Significant OS differences were found depending on age range (P < 0.0001), mean


age (P < 0.0001), marital status at diagnosis (P < 0.0001), pathological grade (P < 0.0001) and tumour orientation (P < 0.0001) (Fig. 1).

In the survival analysis for DSS, patients treated with END showed significantly higher survival rates than patients in the neck observation group (P < 0.0001). The 5-year and 10-year DSS for all causes combined were 73.6 and 64% for the END group, respectively, versus 64.5 and 54.5% for the neck observation group. Additionally, remarkable survival differences were identified depending on age range (P < 0.0001), mean age (P < 0.0001), marital status at diagnosis (P < 0.0001), tumour orientation (P=0.015), pathological grade (P < 0.0001), radiotherapy (P < 0.0001), chemotherapy (P=0.0021) and different treatment modalities (P < 0.0001) (Fig. 2).

Cox regression multivariate analysis

To determine the efficacy of END based on various clinicopathological factors, all significant factors in the





survival analysis were entered into the multivariable analysis based on the Cox regression model.

(CI) = 0.769 (0.675–0.939), P = 0.0069 for DSS; HR (95% CI) = 0.829 (0.732–0.939), P = 0.0031 for OS, neck observation as reference].

The END was favourably associated with better DSS and OS [hazard ratio (HR) 95% confidence interval


The higher pathological grades were adversely associated with DSS and OS [Grade II HR (95% CI)=1.564 (1.257–1.947), P=0.0001; Grade III+IV, HR (95% CI)=2.193 (1.702–2.826), P< 0.0001 for DSS; Grade II, HR (95% CI)=1.311 (1.127–1.525), P=0.0004; Grade III+IV, HR (95% CI)=1.772 (1.47–2.137), P< 0.0001 for OS, Grade I as reference]. The details of the multivariate Cox regression analysis are presented in Fig. 3.

Discussion

Management of the clinical N0 neck tumour is controversial in early OSCC [13]. The metastasis rate of the cervical lymph node is inconsistent according to previous reports. Most importantly, occult metastases exist in early stage OSCC [14]. Previous studies have demonstrated that the occult metastasis rate was approximately 25% in for OSCC patients treated with early-stage END [15–18]. It may be concluded that one in four patients is exposed to the risk of regional recurrence or even developing distant metastasis. However, few studies have clarified whether these patients were T1N0M0 or T2N0M0 and further did not evaluate the effects of performing END on prognosis. This report, to our knowledge, analyses the largest population of T2N0M0 OSCC patients independently to date. We found that performing END effectively improved T2N0M0 OSCC survival and is an independent prognostic indicator.

Based on our results, pathological differentiation is another important prognostic indicator. Compared with grade I well-differentiated OSCC cases, the other three grades (Grades II, III and IV) are adversely associated with DSS and OS. The tumour subtype is an important prognostic factor that has been neglected in previous studies in deciding whether to use END. There are many variants of OSCC, having different biological behaviours and prognosis [19–21]. Almost all SCC variants are registered in the SEER database. To ensure the accuracy of our results, we filtered two variants (8070/3 and 8071/3) and found no significant survival differences between the two variants (P > 0.05).

Regarding oral solid neoplasm, surgical resection remains the most effect treatment modality [22]. Except



for small T1-stage tumour postoperative defects, OSCC surgical treatment often involves resection and functional reconstruction [4]. Surgery is irreplaceable for T2N0M0 OSCC patients. Radiotherapy, chemotherapy or their combination cannot achieve as good results as surgery in oral function recovery. We also studied cases treated with methods other than surgery and evaluated their prognosis. The results demonstrated that there were significant survival differences among the various treatment modalities. Patients treated with surgery showed better prognosis than those treated with other means alone or combinations. Without a doubt, the adjuvant roles of radiotherapy and chemotherapy should be admitted in the positive margin of pathologically undifferentiated cases.

There are variances in the survival rates of different tumour orientations [4]. Controversy sexist in the management of T2N0M0 OSCC arising from maxillary gingiva, alveolus, and hard palate [23]. The low incidence of cervical metastases has historically been considered a hallmark of this disease, and a "watch-and-wait" strategy is typically used to control neck lymph node metastases [24, 25]. The results of survival analysis according to the OSCC orientation showed that group A (floor of mouth) and B (tongue) demonstrated better DSS and OS prognosis than group C (other sites). Based on this finding, we concluded that T2N0M0 OSCC of maxillary gingiva, alveolus, and hard palate should be considered as equally aggressive as those at other sites. However, this conclusion may require further subgroup confirmation.

A few limitations of the publicly available SEER database and the current investigation should be acknowledged. First, not all cases have complete information, including important variables such as pathological grade, HPV status and detailed chemotherapy. Second, due to the lack of oral defect reconstruction data, the role of free flap construction for life quality improvement could not be well established. Third, the follow-up period was variable (0–155 months). Finally, the retrospective nature of the current study may have introduced bias into the overall analysis.

Conclusion

Most previous retrospective or prospective T1/2N0M0 OSCC studies regarding END had small sample sizes. Decisions on whether to proceed with END versus a "wait-and-watch" approach in T1/2N0M0 is controversial for the following reasons. First, the disease has relatively low incidence. Second, early-stage tumours require much longer follow-up durations to identify differences between the two treatment strategies. Finally, and most importantly, radiochemotherapy has shown similar survival rates compared with surgery in early stage OSCC. Despite the limitation of incomplete data and the study itself, the present investigation is the first of its kind using the largest study population from multiple orientations to show that patients with T2N0M0 OSCC benefited from END associating with improved DSS and OS and it was an important independent prognostic factor. Thus, performing END is recommended for patients with T2N0M0 OSCC cases.

Abbreviations

OSCC: Squamous cell carcinoma; OS: Overall survival; AJCC: American Joint Committee on Cancer; END: Elective neck dissection; SEER: Surveillance, Epidemiology, and End Results; ICD-O-3: International Classification of Diseases for Oncology, Third Edition; SPSS: Statistical Package for Social Sciences; DSS: Disease specific survival; HR: Hazard ratio; CI: Confidence interval.

Acknowledgments

We acknowledge American Journal Experts (https://www.aje.com, AJE, Durham, NC, USA) for reviewing the manuscript for grammar consistency (ID: L8LJK8H).

Authors' contributions

FY, ZY and AW contributed to the conception and design of the study; FY, LS and YL performed the experiments, FY, LS and AW collected and analyzed data; FY and LS wrote the manuscript; The authors reviewed and approved the final version of the manuscript.

Funding

This study was supported by Scientific Research Project of Shanghai Municipal Health Commission (202040497).

Availability of data and materials

Study data was publicly available in the SEER database (https://seer.cancer. gov).

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Author details

¹Department of Oral & Maxillofacial Surgery, Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases Shanghai Stomatological Hospital,, Fudan University, 356 Beijing East Road, Shanghai 200001, PR China. ²Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, 356 Beijing East Road, Shanghai 200001, PR China. ³Department of Preventive Medicine, School of Public Health, Shanghai Medical College, Fudan University, Shanghai, China.

Received: 3 December 2020 Accepted: 24 November 2021 Published online: 07 December 2021

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
- Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9.

- Bray F, Ferlay J, Soerjomataram I, Siegel RL. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–24.
- 4. Chinn SB, Myers JN. Oral cavity carcinoma. Current management, controversies, and future directions. J Clin Oncol. 2015;33(29):3269–76.
- Cerezo L, Millán I, Torre A, Aragón G, Otero J. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer. 1992;69(5):1224–34.
- Kelner N, Vartanian JG, Pinto CA, Coutinho-Camillo CM, Kowalski LP. Does elective neck dissection in T1/T2 carcinoma of the oral tongue and floor of the mouth influence recurrence and survival rates? Br J Oral Maxillofac Surg. 2014;52(7):590–7.
- Cao Y, Wang T, Yu C, Guo X, Li C, Li L. Elective neck dissection versus waitand-watch policy for Oral cavity squamous cell carcinoma in early stage: a systematic review and Meta-analysis based on survival data. J Oral Maxillofac Surg. 2019;77(10):2154–67.
- Ebrahimi A, Gil Z, Amit M, Yen T-C, Liao C-T, Chaturvedi P, et al. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1138–48.
- Cai H, Zhu Y, Wang C, Zhang Y, Hou J. Neck nodal recurrence and survival of clinical T1-2 N0 oral squamous cell carcinoma in comparison of elective neck dissection versus observation: a meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129(4):296–310.
- Feng Z, Li JN, Li CZ, Guo CB. Elective neck dissection versus observation in the management of early tongue carcinoma with clinically nodenegative neck: a retrospective study of 229 cases. J Craniomaxillofac Surg. 2014;42(6):806–10.
- Feng Z, Cheng A, Alzahrani S, Li B, Han Z, Ward BB. Elective neck dissection in T1N0M0 Oral squamous cell carcinoma: when is it necessary? J Oral Maxillofac Surg. 2020;78(12):2306–15.
- Fakhry C, Krapcho M, Eisele DW, D'Souza G. Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals. Cancer. 2018;124(10):2125–33.
- Massey C, Dharmarajan A, Bannuru RR, Rebeiz E. Management of N0 neck in early oral squamous cell carcinoma: a systematic review and metaanalysis. Laryngoscope. 2019;129(8):E284–e298.
- Zhangfan D, Tingying X, Jie H, Yihang Y, Qingsong Y. Elective neck dissection versus observation in squamous cell carcinoma of Oral cavity with clinically N0 neck: a systematic review and Meta-analysis of prospective studies. J Oral Maxillofac Surg. 2019;77(1):184–94.
- Huang SF, Kang C-J, Lin C-Y, Fan K-H, Yen T-C, Wang H-M, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112(5):1066–75.
- Keski-Santti H, Atula T, Tornwall J, Koivunen P, Makitie A. Elective neck treatment versus observation in patients with T1/T2 N0 squamous cell carcinoma of oral tongue. Oral Oncol. 2006;42(1):96–101.
- 17. Ho CM, Lam KH, Wei WI, Lau SK, Lam LK. Occult lymph node metastasis in small oral tongue cancers. Head Neck. 1992;14(5):359–63.
- Li Y, Liu K, Ke Y, Zeng Y, Chen M, Li W, et al. Risk factors analysis of pathologically confirmed cervical lymph nodes metastasis in Oral squamous cell carcinoma patients with clinically negative cervical lymph node: results from a Cancer Center of Central China. Head Neck. 1992;14(5):359–63.
- 19. Fritsch VA, Lentsch EJ. Basaloid squamous cell carcinoma of the head and neck: location means everything. J Surg Oncol. 2014;109(6):616–22.
- Alonso JE, Kuan EC, Arshi A, St John MA. A population-based analysis of verrucous carcinoma of the oral cavity. Laryngoscope. 2018;128(2):393–7.
- Bice TC, Tran V, Merkley MA, Newlands SD, van der Sloot PG, Wu S, et al. Disease-specific survival with spindle cell carcinoma of the head and neck. Otolaryngol Head Neck Surg. 2015;153(6):973–80.
- Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009;45(3):201–11.
- Cariati P, Cabello-Serrano A, Monsalve-Iglesias F, Fernadez-Solis J, Martinez-Lara I. Is a "watch and wait strategy" safe to manage clinically N0 squamous cell carcinoma of the upper jaw? Curr Probl Cancer. 2019;43(4):336–43.

- 24. de Bree R, Takes RP, Shah JP, Hamoir M, Kowalski LP, Robbins KT, et al. Elective neck dissection in oral squamous cell carcinoma: past, present and future. Oral Oncol. 2019;90:87–93.
- 25. Abu-Ghanem S, Yehuda M, Carmel NN, Leshno M, Abergel A, Gutfeld O, et al. Elective neck dissection vs observation in early-stage squamous cell carcinoma of the oral tongue with no clinically apparent lymph node metastasis in the neck: a systematic review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2016;142:857–65.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

